Summary
The pharmacokinetics of isosorbide-5-nitrate (IS-5-N) was studied in ten patients on haemodialysis (HD) after a single oral dose of 20 mg IS-5-N, and in six patients on continuous ambulatory peritoneal dialysis (CAPD) after repeated oral doses of 3×20 mg IS-5-N. There was significant removal of IS-5-N from blood during HD; Cmax decreased by about 20%, AUC(0–8 h) by 30% and t1/2 by about 20% from 4.3 to 3.4 h, and plasma clearance was increased by 81 ml/min. No important loss of IS-5-N was observed in patients on CAPD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abshagen U, Betzien G, Endele R, Kaufmann B (1981) Pharmacokinetics of intravenous and oral isosorbide-5-mononitrate. Eur J Clin Pharmacol 20: 269–275
Abshagen U, Spörl-Radun S (1981) First data on effects and pharmacokinetics of isosorbide-5-mononitrate in normal man. Eur J Clin Pharmacol 19: 423–429
Bogaert MG, Rosseel MT, Boelaert J, Daneels R (1981) Fate of isosorbide dinitrate and mononitrates in patients with renal failure. Eur J Clin Pharmacol 21: 73–76
Kösters W, Klotschkoff P, Abshagen U (1981) Pharmakokinetik von Isosorbid-5-mononitrat bei Patienten mit fortgeschrittener Niereninsuffizienz. Med Welt 32: 521–523
Laufen H, Ausmann M, Leitold M (1983) Oral absorption and disposition of isosorbide dinitrate and isosorbide mononitrates in man. Arzneimittelforsch/Drug Res 33: 980–984
Major RM, Taylor T, Chasseaud LF, Darragh A, Lambe RF (1984) Isosorbide-5-mononitrate kinetics. Clin Pharmacol Ther 35: 653–659
Mannebach H, Ohlmeier H, v Möllendorff E, Gleichmann V, Abshagen U (1981) Steady-state-Kinetik von Isosorbid-5-mononitrat bei Patienten mit koronarer Herzkrankheit. Med Welt 32: 517–520
Steudel HC, Volkenandt M, Steudel AT (1983) Pharmacokinetics of isosorbide-5-mononitrate after oral and intravenous administration in patients with liver cirrhosis: First results. Z Kardiol 72 [Suppl 3]: 24–28
Taylor T, Chasseaud LF, Major R, Doyle E, Darragh A (1981) Isosorbide-5-mononitrate pharmacokinetics in humans. Biopharm Drug Disp 2: 255–263
Wood SG, John BA, Chasseaud LF, Major RM, Forrest ME, Bonn R, Darragh A, Lamb RF (1984) Metabolic fate of14C-isosorbide-5-mononitrate in humans. Arzneimittelforsch/Drug Res 34: 1031–1035
Evers J, Krakamp B, Klimkait W, Dickmans HA, Maddock J, Luckow V, Cawello W, Weiß M (1986) Pharmacokinetics of IS-5-N in renal failure. Eur J Clin Pharmacol 30: 349–350
Luckow V, Keppeler D (1984) Dialysabilität von IS-5-N bei Hämodialyse und Peritonealdialyse. Herz Kreisl [Suppl 13]: 17
Levy G (1977) Pharmacokinetics in renal disease. Am J Med 62: 461–465
Lee CSC, Marburg TC (1984) Drug therapy in patients undergoing hemodialysis: Clinical pharmacokinetic considerations. Clin Pharmacokinet 9: 42–66
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Evers, J., Bonn, R., Boertz, A. et al. Pharmacokinetics of isosorbide-5-nitrate during haemodialysis and peritoneal dialysis. Eur J Clin Pharmacol 32, 503–505 (1987). https://doi.org/10.1007/BF00637678
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00637678